Ivesk

Ivermectin, the active ingredient in Ivesk, is an antiparasitic (macrocyclic lactone) presented as an oral tablet for oral use. It treats a range of parasitic infections, including strongyloidiasis, onchocerciasis, scabies, pediculosis and other intestinal nematode diseases, and is prescribed for patients requiring systemic therapy.

GNH USA supplies Ivesk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides reliable global distribution.

Ivermectin is an antiparasitic agent used to treat infections caused by nematodes and ectoparasites.

- Strongyloidiasis: eradicates Strongyloides stercoralis from the intestine, clearing chronic infection. - Onchocerciasis (river blindness): kills microfilariae, reducing ocular and skin manifestations. - Scabies: eliminates Sarcoptes scabiei mites, relieving itching and skin lesions. - Pediculosis (lice infestation): destroys head and body lice, preventing re‑infestation. - Other intestinal nematode infections: removes various soil‑transmitted helminths, improving gastrointestinal health.

Ivermectin may cause a range of adverse reactions, which are classified as common or serious.

Common Side Effects: - Nausea - Diarrhea - Abdominal pain - Dizziness - Headache - Pruritus

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatotoxicity manifested by elevated liver enzymes - Neurologic events including seizures, confusion or ataxia - Hypotension and visual disturbances

When prescribing Ivesk, clinicians should observe the following precautions.

- Pregnancy: safety not established; avoid unless benefits outweigh potential risks. - Breastfeeding: use with caution; monitor infant for possible adverse effects. - Renal or hepatic impairment: consider dose adjustment and monitor function. - Concomitant medications: review for potential interactions before initiating therapy. - Pediatric use: limit to children weighing ≥15 kg; safety in younger children is not confirmed. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Ivermectin can interact with several medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Warfarin: may potentiate anticoagulant effect, increasing bleeding risk. - Benzodiazepines: enhanced central nervous system depression. - Macrolide antibiotics (e.g., erythromycin): can raise ivermectin plasma concentrations.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., ritonavir): may alter ivermectin metabolism. - St. John’s Wort: may reduce ivermectin efficacy by inducing metabolism. - P‑glycoprotein inhibitors (e.g., verapamil): may increase systemic exposure.